- Home
- PENG vs TARS Comparison
PENG vs TARS Comparison
Compare PENG & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | TARS |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PENG | TARS |
|---|---|---|
| Price | $63.85 | $69.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $27.78 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.5M | 831.4K |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | 48.21 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $1,368,794,000.00 | $451,360,000.00 |
| Revenue This Year | $14.55 | $56.43 |
| Revenue Next Year | $16.14 | $30.19 |
| P/E Ratio | $47.21 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $16.04 | $48.20 |
| 52 Week High | $89.86 | $85.25 |
Technical Indicators
Market Signals| Indicator | PENG | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 65.51 |
| Support Level | $57.62 | $60.95 |
| Resistance Level | $75.32 | $73.45 |
| Average True Range (ATR) | 4.33 | 3.30 |
| MACD | 1.16 | 1.12 |
| Stochastic Oscillator | 92.47 | 84.67 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.